Epitherapeutics

Developing novel innovative cancer drugs based on epigenetics.

Launch date

1987

Market cap

Enterprise valuation

€59m (Public information from May 2015)

Foster City California (HQ)

Date	Investors	Amount	Round
-	M Ventures	N/A	-
May 2015	Gilead Sciences	$65.0m Valuation: $65.0m	Acquisition
Total Funding		-

exited

ACQUISITION by Kite Pharma Dec 2022

Recent News about Epitherapeutics